Latest Tenders From Germany

Redevelopment of Apartments

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredients Emtricitabine, Rilpivirine, Tenofovir Disoproxil

Drugs Containing the Active Substance Valproic Acid (Atc: N03ag01)

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Iron(Iii) Derisomaltose (B03ac08).

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Rituximab, Atc L01af01 for the Period August 1St, 2023 - July 31St, 2025

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V (Open House Model)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicinal Products with the Active Ingredient Bimatoprost (S01ee03) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Nilotinib (L01ea03) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.